Open an account

Savara

SVRA · NASDAQ

$4.76+$0.13 (+2.81%)TodayMarket closed ·
Prev close $4.63

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Employees
70
Headquarters
Langhorne, Pennsylvania
Listed
Jun 25, 2001
Sector
Health Care
Industry
Biotechnology
Website
savarapharma.com

SVRA key statistics

Market cap
951.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.45M
Volume
4.42M
Open price
$4.64
High today
$4.99
Low today
$4.60
52 Week high
$7.01
52 Week low
$3.60

Savara (SVRA) at a glance

As of Oct 20, 2026, Savara (SVRA) shares are priced at $4.76, giving the company a market cap of 951.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.60 and $4.99. The current price is 3.5% above the day's low and 4.6% below its high.

Volume so far is 4.42M shares, above the average of 2.45M shares a day.

Over the past year Savara has ranged from $3.60 to $7.01, and now sits 34% of the way up that range.

Savara met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.16 per share against an estimate of -$0.1452.

The average analyst price target is $11.16, 134.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $11.16
Low
$9.09
Now
$4.76
High
$16.80

SVRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 4.5% on average.

  1. Q3 FY24: reported -$0.11 per share against an estimate of -$0.1105
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.1136
  3. Q1 FY25: reported -$0.12 per share against an estimate of -$0.1311
  4. Q2 FY25: reported -$0.14 per share against an estimate of -$0.1243
  5. Q3 FY25: reported -$0.14 per share against an estimate of -$0.1353
  6. Q4 FY25: reported -$0.13 per share against an estimate of -$0.1202
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.1374
  8. Q2 FY26: reported -$0.16 per share against an estimate of -$0.1452

SVRA news

  • Press releaseBusiness Wire

    Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

  • Press releaseBusiness Wire

    Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

  • Press releaseBusiness Wire

    Savara Announces New Employment Inducement Grant

  • Press releaseBusiness Wire

    Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseBusiness Wire

    Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

  • Press releaseBusiness Wire

    Savara Announces New Employment Inducement Grant

  • Press releaseBusiness Wire

    Savara Announces Chief Financial and Administrative Officer Transition

  • Press releaseBusiness Wire

    Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Similar companies

Companies in the same industry as Savara

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.